cyrilzakka/clinical-trials huggingface dataset:
A Preliminary Feasibility Efficacy of Participation in Daily Life Promotion Program

Efficacy of Participation in Daily Life Promotion Program for Patients with Chronic Stroke

The purpose of this three-year research project is to develop an intervention program to promote participation in daily life for patients with chronic stroke and to evaluate its efficacy.

Eligibility Criteria:
Inclusion Criteria:

* Patient with stroke after 6 months.
* Must be able to follow orders and no other cognition impairment, Mini Mental State Examination scale must \>20.

Exclusion Criteria:

* Clinical diagnosis of Dementia or Psychosis.
* Clinical diagnosis of Musculoskeletal disorders or Nervous system diseases.
* Patient with Congestive Heart Failure, Hypertension, Atrial fibrillation.
* Could not communication with others.
* Foreigner.
A Pilot of an Outpatient Regimen of Medical Abortion With Mifepristone and Sublingual Misoprostol in the 11 and 12 Weeks

A pilot study on the acceptability and feasibility with Mifepristone and 400 mg of sub-lingual Misoprostol between 71-77 and 78-84 days of gestation for 50 cases.

The study will enroll 25 women in each gestational age group. All participants will be submitted to routine screening as per current practice at La Rabta Hospital. The eligible women will receive a dose of 200 mg of mifepristone and 400 ug of misoprostol to take at home sublingually .

The first 5 women enrolled in each gestational age group will be asked to return to the clinic 24-48 hours after the initial visit to take misoprostol at the clinic and wait during a 3 hour observational period before returning to their homes. After this initial phase, the women will be asked to self-administer the misoprostol at home 24-48 hours after the administration of mifepristone and to return to the clinic 7-10 days later. At follow-up, a healthcare provider will assure her that her medical abortion is complete and after will ask women to respond to a series of questions in an exit interview.

Eligibility Criteria:
Inclusion Criteria:

* Gestational age of 71-84 days of amenorrhea
* Seeking abortion services
* Prepared and able to sign the consent forms
* Accept to conform to study procedures and scheduled visits

Exclusion Criteria:

* Does not meet study criteria
Zainidip in Renal Artery Stenosis

To evaluate the efficacy of renal artery stent combined with standardized medical therapy as treatment for renal artery stenosis.


Eligibility Criteria:
Inclusion Criteria:

* Age between 40 - 75
* Diameter of stenosis of renal artery or main branch of renal artery ≥60％. If diameter of stenosis is 60% - 75%, pressure difference between proximal and distal end ≥20 mm Hg (1mmHg=0.133kPa) or Captopril renography positive;
* Systolic blood pressure before taking antihypertensive ≥180mmHg and/or diastolic blood pressure ≥110 mmHg; taking three antihypertensive including one diuretics with systolic blood pressure ≥140mmHg and/or ≥90 mmHg;
* length of ipsilateral kidney is greater than 7.0cm.

Exclusion Criteria:

* Estimated glomerular filtration rate (eGFR) \<30 ml/ (min﹒1.73 m 2) \[eGFR (mL/min/1.73 m2) = 186.3 \* serum creatinine (mg/dl) -1.154 \* Age-0.203 \* 0.742 (female)\[11\];
* unstable condition and unable to tolerate interventional therapy;
* anatomy of renal artery pathology not suitable for interventional therapy;
* allergic to dihydropyridines;
* III degree atrioventricular block
* contrast allergy ;
* any known malignant tumor;
* non-compliant, history of alcoholism or drug abuse.
A Novel Device for Neck Pain in Active-duty Military Personnel With Forward Head Posture.

Neck pain is a common complaint among active duty military personnel, and can have tremendous impacts on quality of life and participation in duty-related activities. Treatments for spinal pain in military personnel are typically multimodal, relying upon physical therapy, pharmacological agents, spinal manipulation, and psychotherapy. However, there does not exist a wide body of evidence to support many of these treatments in active-duty military. The Cervigard neck collar was designed to treat posture-related neck pain with minimal effort and time required for treatment by the patient. However, this has yet to be tested experimentally. The objective of this study is to evaluate the treatment effect and safety of a novel device for the treatment of neck pain using self-reported pain and function measures, as well as objective radiological measures of cervical lordosis and head posture. Participants will be randomized to be fitted with and receive the Cervigard neck collar either immediately, or 6-weeks after being screened. Participants will complete neck pain and function questionnaires, and have cervical X-Rays collected at screening, treatment, 6 weeks, and 12 weeks (for the immediate group). Participants will be instructed to wear the collar every day for the duration of the trial. Self-reported neck pain and function measures will be collected, as well as cervical X-Rays, protocol adherence measures, and adverse events. The intervention is expected to reduce neck pain/discomfort, improve function, and improve cervical lordosis.


Eligibility Criteria:
Inclusion Criteria:

* DEERS Eligible
* Age 18 and 45 year old (inclusive)
* Neck pain duration ≥ 3 months without neurological signs and have been seen by a provider.
* Conventional treatments have not decreased neck pain
* Neck pain ≥ 4 on a 0-10 point numerical rating scale (0 = "no pain", 10 = "maximum pain")
* Forward head posture, indicated by forward placement of the head relative to the shoulders.

Exclusion Criteria:

* History of a tumor in the cervical spine and/or head/neck region within the past 6 months.
* Infection involving the cervical spine and/or head/neck region within the past 6 months.
* Generalized medical disorders that would weaken the vertebrae or other tissue structures within the cervical spine region.
* Fracture that is acute and/or still healing
* Spinal deformities (e.g. Fixed kyphosis, Ankylosing spondylosis)
* Medical and/or psychological condition that would preclude safe participation
Utilization of MAsS in Patients Undergoing LT for HCC

The aim of this study is to determine the effects of liver transplantation and standard immunosuppression on body composition in patients with compensated cirrhosis and hepatocellular carcinoma.

The combination of hepatocellular carcinoma and chronic liver disease represents a dual impact on overall metabolism. The major risk factors for chronic liver disease related-hepatocellular carcinoma (HCC) include nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease and hepatitis C virus (HCV), among other etiologies of chronic liver injury.

Of particular interest is how the changing landscape of liver disease impacts the care of patients in the peritransplant period. Numerous recent studies have reported that nonalcoholic steatohepatitis (NASH)-related cirrhosis is the most rapidly growing indication for liver transplantation (LT) in the Western world. NAFLD related HCC is already a leading indication in women. The impact of NAFLD on public health and mortality is substantial: incident decompensated cirrhosis due to NAFLD is predicted to increase by 168%, from 39,230 cases annually in 2015 to 105,430 cases in 2030. The corresponding burden of NAFLD cirrhosis on liver transplantation (LT) is expected to increase by 59%. Finally, 3% per year of cirrhotic patients because of NAFLD, develop HCC and noncirrhotic NAFLD-HCC continues to be an area of investigation.

Since NAFLD is becoming one of the most frequent causes of cirrhosis, HCC, and liver transplantation worldwide, it is crucial to identify changes in the peritransplant period that are associated with adverse muscle health and unfavorable metabolic status in the context of all chronic liver diseases.

Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 75 years
* Diagnosis of cirrhosis and HCC
* Listed or in evaluation for liver transplantation

Exclusion Criteria:

* History of prior solid organ transplantation
* In evaluation or listed for any other solid organ transplant (other than liver transplant)
* Contraindication to MR examination
* Metastatic HCC
Autologous PRP Intra Ovarian Infusion to Restore Ovarian Function in Menopausal Women

Autologous PRP intra ovarian infusion may restore ovarian function, may promote folliculogenesis and may improve hormonal profile of women in menopause.

This triple-blind Randomized Controlled Trial (RCT) aims to investigate the effectiveness of autologous PRP intra ovarian infusion on reactivating ovarian functionality and on promoting folliculogenesis in regard to menopausal women. PRP is blood plasma prepared from fresh whole blood that has been enriched with platelets. It is collected from peripheral veins and contains several growth factors such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor (TGF) and other cytokines all of which stimulate tissue proliferation and growth. PRP has been employed in several medical conditions in Orthopedics, Dermatology, and Ophthalmology for wound healing. It's efficacy in ovarian rejuvenation and reactivation and endometrial regeneration has not been fully elucidated. This study aims to investigate the effect of autologous PRP intra ovarian infusion on restoring ovarian tissue functionality in menopausal women.

Eligibility Criteria:
Inclusion Criteria:

* Age between 45-55 years old
* Amenorrhea for at least 12 months
* Discontinuation of any complementary/adjuvant treatment including hormone replacement, acupuncture, and botanotherapy, for at least three months prior to recruitment.
* Willing to comply with study requirements

Exclusion Criteria:

* Any pathological disorder related to reproductive system anatomy
* Previous POI diagnosis
* Abnormal karyotype
* Endometriosis
* Adenomyosis
* Fibroids and adhesions
* Infections in reproductive system
* Current or previous diagnosis of reproductive system cancer
* History of familiar cancer in reproductive system
* Severe male factor infertility
* Prior referral for PGT
* Ovarian inaccessibility
* Endocrinological disorders (Hypothalamus-Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome)
* BMI\>30 kg/m2 or BMI\<18.5 kg/m2
* Systematic autoimmune disorders
Comparison of Two Different Preload Targets of Stroke Volume Variation During Kidney Transplantation

The investigators sought to compare the effect of two preload targets of stroke volume variation of ≤6% and ≤12% on the postoperative renal function in patients undergoing living donor kidney transplantation. Goal-directed fluid therapy will be performed in both groups to maintain adequate stroke volume, stroke volume variation, mean arterial pressure (or systemic vascular resistance) during kidney transplantation. Only the preload target for giving crystalloid during surgery will be different between groups.

The adequate preload target of fluid management has not yet been established during kidney transplantation. Traditionally, sufficient intravascular volume status has been recommended to maintain perfusion to renal graft. Stroke volume variation was reported to be superior to the traditional target of central venous pressure. In this regard, the investigators sought to compare the effect of two preload targets of stroke volume variation of ≤6% and ≤12% on the postoperative renal function in patients undergoing living donor kidney transplantation. Goal-directed fluid therapy will be performed in both groups to maintain adequate stroke volume, stroke volume variation, mean arterial pressure (or systemic vascular resistance) during kidney transplantation. Only the preload target for giving crystalloid during surgery will be different between groups.

Eligibility Criteria:
Inclusion Criteria:

* Adults patients who are undergoing living donor kidney transplantation with continuous radial artery pressure monitoring

Exclusion Criteria:

* Patients who have cardiac arrhythmia of atrial fibrillation, multiple ventricular premature complex
* Cardiac systolic dysfunction with left ventricle ejection fraction \<50%
* Continuous arterial pressure monitoring at the site other than radial artery.
* Patients who are considered to be intolerant to rapid fluid administration
Cardiopulmonary Resuscitation in Cases of Sudden Cardiac Arrest

Determination the success rate of CPR on adults in Emergency room and predicting the factors that makes CPR is successful.

Cardiac arrest is a medical emergency that requires immediate cardiopulmonary resuscitation (CPR). Return of spontaneous circulation (ROSC) is a core outcome element of cardiopulmonary resuscitation (CPR) both in out-of-hospital cardiac arrest (OHCA) and in-hospital cardiac arrest and has been considered a standard in the evaluation of successful resuscitation.

ROSC was defined as a clinical assessment that shows signs of life comprising of a palpable pulse for at least 20 minutes or generating a blood pressure, the duration of ROSC is key element not only to the efficacy of the chain of survival but also to assess the success of resuscitation in emergency medical services (EMSs).

Worldwide CPR outcomes vary due to differences in the circumstances of cardiac arrest, availability of equipment, and performance of the CPR team. The influencing factors of CPR outcome at the emergency room (ER) are patient characteristics, early detection, immediate CPR, initial shockable rhythm, duration of CPR of less than 10 minutes and advanced cardiac life support.

In Egypt, There has been scarce studies regarding CPR and studies that measure the success rate of CPR and factors determining its success. This study aims to assess the success rate of CPR in Emergency room and factors predicting successful CPR on adults.

Eligibility Criteria:
Inclusion Criteria:

* Resuscitated at the ER in Al Hussein University Hospital.
* Patients Have experienced cardiac arrest.

Exclusion Criteria:

* Patient arresting and receiving CPR inside hospital's other departments.
* Signs of sure death.
* Patient with Multiple Organ Failure Syndrome (M.O.F syndrome
Mobile Thinking Intervention: A Inital Test

This study will test the inital efficacy of a brief mobile intervention targeting biased thinking.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of schizophrenia or related psychotic disorder OR
* Identified as being at clinical high risk for psychosis in symptom interviews

Exclusion Criteria:

* Recent changes in mental health treatment in past month or two months if on depot
Examination of a New Irrigation System for Transanal Irrigation in Children With Fecal Incontinence

The aim of this study is to investigate if a new irrigation system for transanal irrigation (TAI) is effective and more tolerable than the currently used system at the Pediatric Ward at Aarhus University Hospital.

This is a randomized, controlled study.

This study will be performed at Aarhus University Hospital (Denmark) and Aalborg University Hospital (Denmark) following the same protocol.

According to the initial randomization, children will be allocated to treatment with the new system (group A) or with the currently used system (group B). After a period of 6 weeks the child will crossover to use the contrary system.

The hypothesis is that A TAI system specifically developed for children will enhance the child's toleration of irrigation due to fewer reports on pain at insertion which will lead to better compliance. This outcome will induce a comparable or better effect on their fecal incontinence and reduce the needed follow-up period due to fewer incontinence relapse.

Eligibility Criteria:
Inclusion Criteria:

* Fecal incontinence on neurogenic or non-neurogenic basis, where transanal irrigation is indicated.

Exclusion Criteria:

* Morbus Hirschsprungs disease.
* Anorectal malformations.
* Use of medication that are known to cause constipation (e.g. anticholinergics)
Type 1 Diabetes Extension Study

This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D).

This observational study will:

* follow participants to determine how long they continue to produce insulin, and
* will also assess how changes in the immune system over time relate to the ability to produce insulin.

This information could help design better therapies for type 1 diabetes in the future.

Depending upon a participant's level of insulin production, participation may be as short as one return visit or a maximum of five years. Evaluation visits will include:

* Overall health assessments
* Blood and urine collections
* Mixed meal tolerance test (MMTTs) for certain participants, per protocol.

Eligibility Criteria:
Inclusion Criteria:

* Prior participant in an Immune Tolerance Network (ITN) executive committee approved T1DM study.
* Ability to sign informed consent/assent (as applicable for children).

Exclusion Criteria:

* Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; or
* Inability to comply with the study visit schedule and required assessments.
Optimization of the ex Vivo Challenge: Reproductive Infections and Contraception

The development of surrogates to predict HIV prevention product safety and efficacy is a high priority. An ex vivo challenge model is one such promising surrogate. Colonic tissue exposed to rectally applied microbicides in vivo and then challenged with HIV in the lab showed significant reduction in HIV replication when compared to tissue exposed to placebo gel. Currently, the ex vivo challenge model for ectocervical and vaginal tissue is under development at the Dezzutti lab at the Magee Womens Research Institute in Pittsburgh, PA. Currently the Reproductive Infectious Disease Research Group is conducting a study designed to answer important questions about the ex vivo challenge model:which HIV virus is the best to use in the laboratory and what is the best indicator of HIV infection. The proposed study delineated here will investigate the effect of BV, HSV and contraceptive use on the model . There will be two arms to the study; the first will investigate the impact of HSV and BV status and the second, contraceptive use. Vaginal and cervical biopsies will be collected from participants for the ex vivo challenge model.


Eligibility Criteria:
Inclusion Criteria:

1. Age 18-45
2. HIV uninfected. Note: if a woman participated in a recent research study and has an HIV test result available from that study, this will suffice provided the date of the test is within 6 months of the enrollment visit for this trial. Otherwise, the potential participant should undergo testing at the first study visit.
3. Willing and able to give informed consent to take place in the study
4. Willing to undergo a pelvic examination and genital biopsies and HIV and HSV testing
5. Willing to provide contact information
6. Agree to be sexually abstinent for two weeks beginning one week prior to the enrollment visit

Exclusion Criteria:

1. Menopausal
2. Pregnant or within 90 days of last pregnancy
3. Hysterectomy
4. Use of a diaphragm, NuvaRing or spermicide for contraception
5. Reports a course of antibiotic therapy in the 14 days prior to enrollment
6. Known history of platelet disorder or bleeding disorder
7. Participation in another microbicide or contraceptive study or a study involving cervical and/or vaginal biopsies within one month of enrollment
8. Pelvic exam findings concerning for cervicitis including abnormal cervical discharge, erythema and edema
9. Use of any spermicide or spermicide-lubricated condom within one week of enrollment.
10. Use of any internal vaginal device or product with the exception of tampons within one week of enrollment
11. Any other condition that in the opinion of the site investigator would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
COACH-Cog Intervention Adaptation Focus Groups

To gather key stakeholder input for feedback on the adaption of the COACH GA intervention (i.e., develop COACH-Cog) to enhance triadic communication among oncologists, care partners and patients with ADRD.


Eligibility Criteria:
Inclusion/Exclusion Criteria:

The inclusion and exclusion criteria for participants are that they must be able to consent for themselves and must speak English.

For the medical oncologist focus group, participants must be a medical oncologist.

For the clinicians with expertise in cognitive impairment and dementia focus group, participants must be a clinician that treats patients with cognitive impairment and dementia.

For the older patients with cancer focus group, participants must be older than 65 years of age and have or had cancer.

For the caregivers of patients with dementia focus group, participants must be caregivers of patients with dementia or cognitive impairment.
Evaluation of Predictive Factors for Recurrence of Persistent Atrial Fibrillation After Ablation

This is a single-center, retrospective, observational study based on data extracted from the medical records of patients who underwent a procedure for persistent atrial fibrillation ablation.


Eligibility Criteria:
Inclusion Criteria:

* Patient aged 18 years or older, who has been informed about the research
* Patient who underwent a procedure for persistent atrial fibrillation ablation at Clairval Hospital since January 2014
* Patient for whom data regarding the ablation procedure are available

Exclusion criteria:

* Patient under legal protection, guardianship, or conservatorship
* Patient who has expressed opposition to the use of their medical data (by completing and returning the opt-out form provided)
A Clinical Trial Follow-up Study of the Genesis II Posterior Stabilized Total Knee Replacement

The purpose of this study is to look at the outcomes of the GENESIS II Posterior Stabilized Total Knee Replacement.


Eligibility Criteria:
Inclusion Criteria:

* A combined deformity of \<30 degrees = group 1
* A combined deformity of \>30 degrees = group 2
* Patient is willing to consent to participate in the study
* Patient is available for follow-up through at least 2 years but preferably 5 years
* Patient has met acceptable preoperative medical clearance and is free of or treated for medical conditions that would pose excessive operative risk
* Patients who are fluent in English and are able to understand their role in a clinical trial

Exclusion Criteria:

* Active, local infection or systemic infection
* Fibromyalgia patients
* Patients whom, as judged by the surgeon, are not capable of understanding the informed consent or the requirements of the protocol and or are reasonably unlikely to be compliant with the prescribed routine and the follow-up evaluation schedule